natgillin/translations-raw huggingface dataset:
Co-administration of Aptivus, co- administered with low dose ritonavir, and pravastatin should be initiated with the lowest dose (10 mg/day) of pravastatin, titrated to treatment response, and accompanied with careful clinical monitoring for pravastatin associated symptoms as described in the label of pravastatin.
Dajanje zdravila Aptivusob hkratnem dajanju majhnih odmerkov ritonavirja sočasno s pravastatinom je treba začeti z najmanjšim odmerkom (10 mg na dan) pravastatina in odmerek povečevati do odziva.
Co-administration of Aptivus, co- administered with low dose ritonavir, and rosuvastatin should be initiated with the lowest dose (5 mg/day) of rosuvastatin, titrated to treatment response, and
Dajanje zdravila Aptivus ob hkratnem dajanju majhnih odmerkov ritonavirja sočasno z rosuvastatinom je treba začeti z najmanjšim odmerkom (5 mg na dan) rosuvastatina in ga povečevati do odziva, ob skrbnem spremljanju zaradi simptomov, ki jih povzroča rosuvastatin.
Co-administration of asenapine with known inhibitors, inducers or substrates of these metabolic pathways has been studied in a number of drug- drug interaction studies (see section 4.5).
Sočasno uporabo asenapina z znanimi zaviralci, induktorji ali substrati teh presnovnih poti so proučili v več študijah interakcij med zdravili (glejte poglavje 4.5).
Co-administration of atazanavir/ritonavir and Atripla is not recommended.
atazanavir/ritonavir/efavirenz
Co-administration of atorvastatin and
Sočasna uporaba atorvastatina in telaprevirja
Co-administration of atorvastatin with Genvoya is not recommended.
Sočasno dajanje atorvastatina z zdravilom Genvoya se ne priporoča.
Co-administration of atorvastatin with Stribild is not recommended.
Sočasno dajanje atorvastatina z zdravilom Stribild se ne priporoča.
Co-administration of atorvastatin with Tybost is not recommended.
Sočasno dajanje atorvastatina z zdravilom Tybost se ne priporoča.
Co-administration of Atripla and didanosine is not recommended (see section 4.4).
Atripla, se zdravilo Atripla
Co-administration of Atripla and didanosine is not recommended since exposure to didanosine is significantly increased following co-administration with tenofovir disoproxil fumarate that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Sočasne uporabe zdravila Atripla in didanozina ne priporočamo, saj se izpostavljenost didanozinu po sočasni uporabi s dizoproksiltenofovirijevim fumaratom pomembno poveča, kar lahko poveča tveganje za pojav neželenih učinkov, povezanih z didanozinom (glejte poglavje 4.5).
Co-administration of axitinib with strong CYP3A4/5 inducers (e.g. rifampicin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentin, phenobarbital, and Hypericum perforatum [St. John’s wort]) may decrease axitinib plasma concentrations.
Sočasna uporaba aksitiniba skupaj z močnimi induktorji CYP3A4/5 (npr. rifampicin, deksametazon, fenitoin, karbamazepin, rifabutin, rifapentin, fenobarbital in Hypericum perforatum [šentjanževka]) lahko zmanjša plazemske koncentracije aksitiniba.
Co-administration of axitinib with strong CYP3A4/5 inducers may decrease axitinib plasma concentrations (see section 4.5).
Sočasna uporaba aksitiniba skupaj z močnimi induktorji CYP3A4/5 lahko zmanjša plazemske koncentracije aksitiniba (glejte poglavje 4.5).
Co-administration of axitinib with strong CYP3A4/5 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, erythromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin) may increase axitinib plasma concentrations.
Sočasna uporaba aksitiniba skupaj z močnimi zaviralci CYP3A4/5 (npr. ketokonazol, itrakonazol, klaritromicin, eritomicin, atazanavir, indinavir, nefazodon, nelfinavir, ritonavir, sakvinavir in telitromicin) lahko poveča plazemske koncentracije aksitiniba.
Co-administration of axitinib with strong CYP3A4/5 inhibitors may increase axitinib plasma concentrations (see section 4.5).
Sočasna uporaba aksitiniba skupaj z močnimi zaviralci CYP3A4/5 lahko poveča plazemske koncentracije aksitiniba (glejte poglavje 4.5).
Co-administration of boceprevir with Aptivus/ritonavir is not recommended.
Sočasne uporabe boceprevirja in zdravila Aptivus/ritonavirja se ne priporoča.
Co-administration of boceprevir with medicines that induce or inhibit CYP3A4/5 could
Pri hkratnem dajanju boceprevirja in zdravil, ki inducirajo ali zavirajo CYP3A4/5, bi se lahko izpostavljenost povečala ali zmanjšala.
Co-administration of boosted PREZISTA with these anticoagulants may increase concentrations of the anticoagulant.
Sočasna uporaba okrepljenega zdravila PREZISTA z navedenimi antikoagulanti lahko zviša njihove koncentracije.
Co-administration of bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19) 125 mg twice daily with oral sildenafil 80 mg three times a day (at steady state) concomitantly administered during 6 days in healthy volunteers resulted in a 63 % decrease of sildenafil AUC.
Sočasna uporaba bosentana (zmeren induktor CYP3A4, CYP2C9 in morda CYP2C19) v odmerku 125 mg dvakrat na dan in peroralnega sildenafila v odmerku 80 mg trikrat na dan (v stanju dinamičnega ravnovesja), 6 dni pri zdravih prostovoljcih je povzročila 63 % zmanjšanje AUC sildenafila.
Co-administration of bupropion with drugs that are metabolised by CYP2D6 isozyme including certain antidepressants (SSRIs and many tricyclic antidepressants, e.g. desipramine, imipramine, paroxetine), antipsychotics (e.g., haloperidol, risperidone and thioridazine), beta-blockers (e.g., metoprolol) and Type 1C antiarrhythmics (e.g., propafenone and flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medicinal product.
Sočasna uporaba bupropiona in zdravil, ki jih presnavlja izoencim CYP2D6, vključno z nekaterimi antidepresivi (SSRI in številni triciklični antidepresivi, npr. dezipramin, imipramin, paroksetin), antipsihotiki (npr. haloperidol, risperidon in tioridazin), betaadrenergičnimi antagonisti (npr. metoprolol) in antiaritmiki skupine 1C (npr. propafenon in flekainid), mora potekati previdno, uvesti pa jo je treba na spodnji meji razpona odmerkov za sočasno uporabljeno zdravilo.
Co-administration of carbamazepine, a P-gp inducer, decreases tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Sočasno dajanje karbamazepina, induktorja P-gp, zmanjša koncentracije alafenamidtenofovirata v plazmi, kar ima lahko za posledico izgubo terapevtskega učinka in razvoj rezistence.
Co-administration of ceritinib with CYP3A substrates known to have narrow therapeutic indices (e.g. astemizole, cisapride, ciclosporin, ergotamine, fentanyl, pimozide, quinidine, tacrolimus, alfentanil and sirolimus) and CYP2C9 substrates known to have narrow therapeutic indices (e.g. phenytoin and warfarin) should be avoided.
Izogibati se je treba sočasnemu odmerjanju ceritiniba s substrati CYP3A z ugotovljenim nizkim terapevtskim indeksom (kot so astemizol, cisaprid, ciklosporin, ergotamin, fentanil, pimozid, kinidin, takrolimus, alfentanil in sirolimus) in s substrati CYP2C9 z ugotovljenim nizkim terapevtskim indeksom (kot sta fenitoin in varfarin).
Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.
Sočasna uporaba holestiramina ali holestipola s propranololom je povzročila do 50-odstotno znižanje koncentracij propranolola.
Co-administration of ciclosporin is expected to increase plasma concentrations of rilpivirine (inhibition of CYP3A) and tenofovir alafenamide (inhibition of P-gp).
Pričakuje se, da bo sočasna uporaba ciklosporina povečala koncentracije rilpivirina (zaviranje encimov CYP3A) in alafenamidtenofovirata (indukcija P-gp) v plazmi.
Co-administration of ciclosporin, a potent P-gp inhibitor, is expected to increase plasma concentrations of tenofovir alafenamide.
Pričakuje se, da bo sočasno dajanje ciklosporina, močnega zaviralca P-gp, povečala koncentracije alafenamidtenofovirata v plazmi.
Co-administration of ciprofloxacin with ivacaftor did not affect the exposure of ivacaftor.
Pomen teh ugotovitev za ljudi ni znan.
Co-administration of CRESEMBA with potent CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long-acting barbiturates (e.g., phenobarbital), phenytoin and St. John‟s wort, or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine, is contraindicated, since these medicinal products can significantly decrease plasma concentrations of isavuconazole (see section 4.3).
Sočasna uporaba zdravila CRESEMBA z močnimi induktorji CYP3A4/5, kot so rifampicin, rifabutin, karbamazepin, dolgodelujoči barbiturati (npr. fenobarbital), fenitoin in šentjanţevka ali z zmernimi induktorji CYP3A4/5, kot so efavirenz, nafcilin in etravirin, je kontraindicirana, saj lahko ta zdravila znatno zmanjšajo koncentracije izavukonazola v plazmi (glejte poglavje 4.3).
Co-administration of darunavir and ritonavir and medicinal products primarily metabolised by CYP3A and/or CYP2D6 or transported by P-gp may result in increased systemic exposure to such medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
Sočasna uporaba učinkovin darunavir/ritonavir z zdravili, ki se presnavljajo predvsem s CYP3A in/ali CYP26D ali jih prenaša P- gp, lahko povzroči zvečano sistemsko izpostavljenost takšnim zdravilom, kar bi lahko zvečalo ali podaljšalo njihov terapevtski učinek in neželene učinke.
Co-administration of darunavir and ritonavir and medicinal products which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result in increased plasma concentrations of these medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
Sočasna uporaba darunavirja, ritonavirja z zdravili, ki se presnavljajo predvsem s CYP2D6 (flekainid, propafenon, metoprolol), lahko povzroči zvečanje plazemskih koncentracij teh zdravil, kar lahko zveča ali podaljša njihov terapevtski učinek in neželene učinke.
Co-administration of darunavir and ritonavir and other medicinal products that inhibit CYP3A may decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of darunavir and ritonavir (e.g. indinavir, systemic azoles like ketoconazole and clotrimazole).
Sočasna uporaba darunavirja in ritonavirja z zdravili, ki inhibirajo encim CYP3A, lahko zmanjša očistek darunavirja in ritonavirja in posledično zveča plazemske koncentracije darunavirja in ritonavirja (npr. indinavir, sistemsko dani azoli, kot sta ketokonazol in klotrimazol).
Co-administration of darunavir and ritonavir with medicinal products which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result in increased plasma concentrations of these medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
Sočasna uporaba darunavirja, ritonavirja z zdravili, ki se presnavljajo predvsem s CYP2D6 (flekainid, propafenon, metoprolol), lahko povzroči zvečanje plazemskih koncentracij teh zdravil, kar lahko zveča ali podaljša njihov terapevtski učinek in neželene učinke.
Co-administration of darunavir/cobicistat with weak to moderate CYP3A inducers (e.g. efavirenz, etravirine, nevirapine, boceprevir, telaprevir, fluticasone, and bosentan) is not recommended (see interaction table below).
Sočasna uporaba učinkovin darunavir/kobicistat s šibkimi do zmernimi induktorji CYP3A (npr. efavirenz, etravirin, nevirapin, boceprevir, telaprevir, flutikazon in bosentan) ni priporočljiva (glejte spodnjo preglednico interakcij).
co-administration of darunavir/ritonavir or
lopinavir/ritonavir.
Co-administration of darunavir/ritonavir with medicinal products primarily metabolised by CYP3A and/or CYP2D6 or transported by P-gp may result in increased systemic exposure to such medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
Sočasna uporaba učinkovin darunavir/ritonavir z zdravili, ki se presnavljajo predvsem s CYP3A in/ali CYP26D ali jih prenaša P- gp, lahko povzroči zvečano sistemsko izpostavljenost takšnim zdravilom, kar bi lahko zvečalo ali podaljšalo njihov terapevtski učinek in neželene učinke.
Co-administration of dasabuvir with ombitasvir/paritaprevir/ritonavir can decrease exposures of medicinal products that are metabolized by CYP2C19 (e.g. lansoprazole, esomeprazole, s- mephenytoin), which may require dose adjustment/clinical monitoring.
Sočasna uporaba dasabuvirja s kombinacijo ombitasvir/paritaprevir/ritonavir lahko zmanjša izpostavljenost zdravilom, ki se presnavljajo s CYP2C19 (npr. lansoprazol, esomeprazol, s- mefenitoin), zaradi česar bo morda potrebna prilagoditev odmerka in klinično spremljanje.
Co-administration of delamanid with quinolones
Sočasna uporaba delamanida s kinoloni
Co-administration of Descovy with other medicinal products that inhibit P-gp (e.g., cobicistat, ritonavir, ciclosporin) are expected to increase the absorption and plasma concentration of tenofovir alafenamide.
Pričakuje se, da sočasno dajanje zdravila Descovy z drugimi zdravili, ki zavirajo P-gp (npr. kobicistatom, ritonavirjem, ciklosporinom), poveča absorpcijo in koncentracijo alafenamidtenofovirata v plazmi.
Co-administration of Descovy with St. John’s wort is not recommended.
Sočasno dajanje zdravila Descovy s šentjanževko se ne priporoča.
Co-administration of dolutegravir and other medicinal products that inhibit these enzymes may increase dolutegravir plasma concentration (see Table 1).
Sočasno jemanje dolutegravirja in drugih zdravil, ki zavirajo te encime, lahko poveča plazemske koncentracije dolutegravirja (glejte Preglednico 1).
Co-administration of DUTREBIS with high doses of co-trimoxazole for the treatment of Pneumocystis carinii pneumonia (PCP) and toxoplasmosis should be avoided.
Sočasni uporabi zdravila DUTREBIS z velikimi odmerki kotrimoksazola za zdravljenje pljučnice s Pneumocystis carinii (PCP) in toksoplazmoze se je treba izogibati.
Co-administration of efavirenz
Pri sočasni uporabi efavirenza z
Co-administration of efavirenz
Sočasne uporabe efavirenza in
Co-administration of efavirenz (enzyme inducer) based
Sočasna uporaba shem na podlagi efavirenza (ki je
Co-administration of efavirenz (enzyme inducer) based
Sočasna uporaba shem na podlagi efavirenza (ki je induktor
Co-administration of efavirenz and elvitegravir is expected to decrease elvitegravir plasma concentrations which may result in loss of therapeutic effect and possible development of resistance.
Pričakuje se, da bo sočasno dajanje efavirenza in elvitegravirja zmanjšalo koncentracije elvitegravirja v plazmi, kar lahko povzroči izgubo terapevtskega učinka in možen razvoj rezistence.
Co-administration of efavirenz and REYATAZ is not recommended (see section 4.4)
Sočasne uporabe efavirenza in zdravila REYATAZ ne priporočamo (glejte poglavje 4.4).
Co-administration of efavirenz and St. John’s wort or herbal preparations containing St. John’s wort is contraindicated.
Sočasna uporaba efavirenza in šentjanževke ali pripravkov rastlinskega izvora, ki vsebujejo šentjanževko, je kontraindicirana.
co-administration of efavirenz with
etonogestrel in efavirenz,
co-administration of efavirenz with
uporaba efavirenza in metadona
Co-administration of efavirenz with medicinal products that alter gastric pH would not be expected to affect efavirenz absorption.
zdravili, ki spremenijo želodčni pH, ne pričakujemo vpliva na absorpcijo efavirenza.
Co-administration of efavirenz with REYATAZ/ritonavir is not recommended (see section 4.4)
Sočasne uporabe efavirenza in zdravila REYATAZ/ritonavirja se ne priporoča (glejte poglavje 4.4).
Co-administration of efavirenz with the fixed combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate is not recommended unless needed for dose adjustment (for example, with rifampicin).
Sočasne uporabe efavirenza in tablete s fiksno kombinacijo, ki vsebuje efavirenz, emtricitabin in dizoproksiltenofovirat fumarat, ne priporočamo, razen če je to potrebno za prilagoditev odmerka (npr. z rifampicinom).
Co-administration of efavirenz with the fixed combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate, is not recommended unless needed for dose adjustment (for example, with rifampicin).
Sočasne uporabe efavirenza in tablete s fiksno kombinacijo, ki vsebuje efavirenz, emtricitabin in dizoproksiltenofovirat fumarat, ne priporočamo, razen če je to potrebno za prilagoditev odmerka (npr. z rifampicinom).
Co-administration of efavirenz with the fixed-combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate is not recommended, unless needed for dose adjustment (for example, with rifampicin).
Sočasne uporabe efavirenza in tablete s fiksno kombinacijo, ki vsebuje efavirenz, emtricitabin in dizoproksiltenofovirat fumarat, ne priporočamo, razen če je to potrebno za prilagoditev odmerka (npr. z rifampicinom).
Co-administration of eltrombopag with lopinavir/ritonavir (LPV/RTV) may cause a decrease in the concentration of eltrombopag.
Pri sočasni uporabi eltrombopaga in lopinavirja/ritonavirja (LPV/RTV) se lahko koncentracija eltrombopaga zmanjša.
Co-administration of eluxadoline with cyclosporine (an OATP1B1 inhibitor) increased eluxadoline exposure by approximately 5-fold (see sections 4.3 and 4.5).
Pri sočasni uporabi eluksadolina s ciklosporinom (zaviralcem OATP1B1) se je izpostavljenost eluksadolinu povečala za približno 5-krat (glejte poglavji 4.3 in 4.5).
Co-administration of elvitegravir with oral contraceptives containing progestagens other than norgestimate have not been studied and, therefore, should be avoided.
Sočasne uporabe elvitegravirja s peroralnimi kontraceptivi, ki vsebujejo druge progestagene kot norgestimat, niso preučili, zato se ji je treba izogniti.
Co-administration of Epclusa with efavirenz/ emtricitabine/ tenofovir disoproxil fumarate is expected to decrease the concentration of velpatasvir.
Pri uporabi z efavirenzom/emtricitabinom/dizo- proksiltenofovirijev fumaratom se pričakuje, da bo zdravilo Epclusa zmanjšalo koncentracijo velpatasvirja.
Co-administration of Epclusa with rifapentine is expected to decrease the concentration of sofosbuvir and velpatasvir, leading to reduced therapeutic effect of Epclusa.
Pričakuje se, da bo sočasno dajanje zdravila Epclusaz rifapentinom zmanjšalo koncentracije sofosbuvirja in velpatasvirja, kar zmanjša terapevtski učinek zdravila Epclusa.
Co-administration of Esbriet and 750 mg of ciprofloxacin (a moderate inhibitor of CYP1A2) increased the exposure to pirfenidone by 81%.
Sočasno dajanje zdravila Esbriet in 750 mg ciprofloksacina (zmernega inhibitorja CYP1A2) je zvišalo izpostavitev pirfenidonu za 81 %.
Co-administration of eslicarbazepine acetate 1,200 mg once daily with warfarin showed a small (23%) but statistically significant decrease in exposure to S-warfarin.
Pri sočasni uporabi 1.200 mg eslikarbazepinacetata enkrat na dan in varfarina so opazili majhno (23- odstotno), vendar statistično pomembno zmanjšanje izpostavljenosti S-varfarinu.
Co-administration of eslicarbazepine acetate 1,200 mg once daily with warfarin showed a small (23%), but statistically significant decrease in exposure to S-warfarin.
Pri sočasni uporabi 1.200 mg eslikarbazepinacetata enkrat na dan in varfarina so opazili majhno (23- odstotno), vendar statistično pomembno zmanjšanje izpostavljenosti S-varfarinu.
Co-administration of Eviplera and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Sočasna uporaba zdravila Eviplera in didanozina ni priporočljiva, saj povzroča povečanje sistemske izpostavljenosti didanozinu za 40–60 %, kar lahko poveča tveganje za pojav neželenih učinkov, povezanih z didanozinom (glejte poglavje 4.5).
Co-administration of Eviplera and didanosine is not recommended since exposure to didanosine is significantly increased following co-administration with tenofovir disoproxil fumarate, which may increase the risk of didanosine-related adverse reactions (see section 4.5).
Sočasna uporaba zdravila Eviplera in didanozina ni priporočljiva, saj se izpostavljenost didanozinu znatno poveča po sočasnem dajanju dizoproksiltenofovirijevega fumarata, kar lahko poveča tveganje pojava neželenih učinkov, povezanih z didanozinom (glejte poglavje 4.5).
Co-administration of EVOTAZ and
Sočasna uporaba zdravila EVOTAZ
Co-administration of EVOTAZ in patients receiving medicinal products that are substrates of the transporters P-gp, BCRP, MATE1, OATP1B1 and OATP1B3 may result in increased plasma concentrations of the co- administered medicinal products (see section 4.4).
Pri bolnikih, ki se zdravijo z zdravili, ki so substrati za prenašalce P-gp, BCRP, MATE1, OATP1B1 ali OATP1B3, se pri sočasni uporabi zdravila EVOTAZ lahko povečajo plazemske koncentracije sočasno uporabljenih zdravil (glejte poglavje 4.4).
Co-administration of EVOTAZ with
Sočasna uporaba zdravila EVOTAZ
Co-administration of Exviera with medicinal products that are strong or moderate enzyme inducers is expected to decrease dasabuvir plasma concentrations and reduce its therapeutic effect (see section
Sočasna uporaba zdravila Exviera z zdravili, ki močno ali zmerno inducirajo encime, predvidoma zmanjša koncentracijo dasabuvirja v plazmi in njegov terapevtski učinek (glejte poglavje 4.5).
Co-administration of Exviera with other antivirals has not been studied and, therefore, cannot be recommended.
Sočasna uporaba zdravila Exviera z drugimi protivirusnimi zdravili ni bila raziskana in je zato ni mogoče priporočati.
Co-administration of fentanyl with a serotoninergic agent, such as a Selective Serotonin Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening condition.
Sočasna uporaba fentanila s serotoninergično učinkovino, kot je selektiven zaviralec ponovnega privzema serotonina (SSRI), zaviralec ponovnega privzema serotonina in noradrenalina (SNRI) ali zaviralec monoamin-oksidaze (MAO), lahko poveča tveganje za potencialno smrtno nevarni serotoninski sindrom.
Co-administration of fluconazole or isavuconazole may increase plasma concentrations of tenofovir alafenamide.
Sočasno dajanje flukonazola ali izavukonazola lahko poveča koncentracije alafenamidtenofovirata v plazmi.
Co-administration of fusidic acid and Invirase/ritonavir can cause increased plasma concentration of both fusidic acid and saquinavir/ritonavir.
Sočasna uporaba fusidne kisline in zdravila Invirase/ritonavirja lahko poveča plazemske koncentracije tako fusidne kisline kot sakvinavirja/ritonavirja.
Co-administration of Genvoya and other medicinal products primarily metabolised by CYP3A such as amiodarone, quinidine, cisapride, pimozide, alfuzosin and sildenafil for pulmonary arterial hypertension is contraindicated (see section 4.3).
Sočasna uporaba zdravila Genvoya in drugih zdravil, ki jih pretežno presnavlja CYP3A, kot so amiodaron, kinidin, cisaprid, pimozid, alfuzosin in sildenafil za pljučno arterijsko hipertenzijo, je kontraindicirana (glejte poglavje 4.3).
Co-administration of Genvoya and some medicinal products that induce CYP3A such as St. John’s wort (Hypericum perforatum), rifampicin, carbamazepine, phenobarbital, and phenytoin may result in significantly decreased cobicistat and elvitegravir plasma concentrations, which may result in loss of therapeutic effect and development of resistance (see section 4.3).
Sočasno dajanje zdravila Genvoya in nekaterih zdravil, ki inducirajo CYP3A, kot so šentjanževka (Hypericum perforatum), rifampicin, karbamazepin, fenobarbital in fenitoin, lahko povzroči znatno zmanjšanje koncentracij kobicistata in elvitegravirja v plazmi, kar ima lahko za posledico izgubo terapevtskega učinka in razvoj rezistence (glejte poglavje 4.3).
Co-administration of Genvoya and triazolam is contraindicated (see section 4.3).
Sočasno dajanje zdravila Genvoya in triazolama je kontraindicirano (glejte poglavje 4.3).